The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Self-citationThe DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Cited by
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“Although the precise mechanisms that explain PARP1 trapping are still unclear, two have been proposed: (i) PARPi either prevents the release of PARP1 from DNA by inhibiting autoPARylation [11] or (ii) PARPi binding to the catalytic site causes allosteric changes in the PARP1 structure enhancing DNA avidity [3, 10, 12].”
BackgroundLaying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Self-citationPARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449
Clinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 374
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
Okajima, D., Yasuda, S., Maejima, T., Karibe, T., Sakurai, K., Aida, T., Toki, T., Yamaguchi, J., Kitamura, M., Kamei, R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0206 · Cited by 339
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337
Self-citationStructural basis for allosteric PARP-1 retention on DNA breaks
Zandarashvili, L., Langelier, M.-F., Velagapudi, U. K., Hancock, M. A., Steffen, J. D., Billur, R., Hannan, Z. M., Wicks, A. J., Krastev, D. B., Pettitt, S. J., et al. (2020) · Science · doi:10.1126/science.aax6367 · Cited by 320
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Self-citationHopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270
PARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 269
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
Shastry, M., Jacob, S., Rugo, H. S., & Hamilton, E. (2022) · The Breast · doi:10.1016/j.breast.2022.10.007 · Cited by 143
Füredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Marzi, L., Szabova, L., Gordon, M., Weaver Ohler, Z., Sharan, S. K., Beshiri, M. L., Etemadi, M., Murai, J., Kelly, K., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0419 · Cited by 60
Self-citationDemuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., et al. (2024) · Cancers · doi:10.3390/cancers16203441 · Cited by 14
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
Background
Metadata
- Authors
- Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 349
- Issue
- 3
- Pages
- 408-416
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2139802796
- Cited by
- 293
- References
- 42
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.